◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SVRA

Savara Inc (SVRA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-17

Savara Inc (SVRA) operates in the BIOTECHNOLOGY industry and is headquartered in Yardley, United States with about 70 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, SVRA reported $0M in revenue and ($119M) in net income.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.

Interactive charts & full statements →

SVRA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—
Gross Profit	—	$0M	($78M)	($44M)	($28M)	($29M)	($35M)	($39M)	($1M)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—
Gross Margin %	—	—	—	—	—	-2899100.0%	-13533.5%	—	—	—	100.0%	-270270.4%	100.0%	—	—	—	100.0%	100.0%	100.0%	100.0%	—
Operating Income (EBIT)	($144M)	($124M)	($103M)	($60M)	($39M)	($41M)	($49M)	($79M)	($70M)	($30M)	($11M)	($39M)	($29M)	($22M)	($16M)	($13M)	($9M)	($11M)	($27M)	($24M)	($30M)
Operating Margin %	—	—	—	—	—	-4147700.0%	-19182.9%	—	—	—	-2737.0%	-72912963.0%	-1891408.3%	—	—	—	-1746.5%	-3761.9%	-5462.0%	-4862.2%	—
Net Income	($139M)	($119M)	($96M)	($55M)	($38M)	($43M)	($50M)	($78M)	($62M)	($30M)	($11M)	($40M)	($29M)	($21M)	($16M)	($13M)	($8M)	($11M)	($27M)	($22M)	($29M)
Net Margin %	—	—	—	—	—	-4301400.0%	-19305.5%	—	—	—	-2730.8%	-73781481.5%	-1854134.4%	—	—	—	-1728.3%	-3775.0%	-5329.5%	-4428.4%	—
EBITDA	($139M)	($119M)	($102M)	($59M)	($38M)	($40M)	($46M)	($50M)	($70M)	($32M)	($10M)	($39M)	($29M)	($21M)	($15M)	($13M)	($8M)	($11M)	($27M)	($24M)	($29M)
Earnings Per Share (EPS)	$-0.59	$-0.53	$-0.48	$-0.33	$-0.25	$-0.32	$-0.84	$-1.95	$-1.85	$-1.70	$-3.27	$-17.19	$-16.41	$-19.63	$-22.86	$-32.94	$-44.88	$-169.85	$-516.69	$-430.96	$-693.77
Shares Outstanding (M)	254M	222M	198M	165M	153M	134M	59M	40M	33M	—	3M	2M	2M	1M	1M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVRA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	—	$0M	$0M	($21M)	$0M	($1M)	$0M	($20M)
Gross Margin %	—	—	—	—	—	—	-25.7%	—
Operating Income (EBIT)	($41M)	($39M)	($33M)	($30M)	($31M)	($28M)	($31M)	($26M)
Operating Margin %	—	—	—	—	—	—	-11461.0%	—
Net Income	($40M)	($37M)	($32M)	($30M)	($30M)	($27M)	($29M)	($24M)
Net Margin %	—	—	—	—	—	—	-10677.9%	—
EBITDA	($40M)	($37M)	($32M)	($29M)	($30M)	($28M)	($29M)	($24M)
Earnings Per Share (EPS)	$-0.16	$-0.15	$-0.14	$-0.14	$-0.14	$-0.12	$-0.15	$-0.11
Shares Outstanding (M)	254M	253M	222M	216M	216M	216M	198M	212M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVRA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($110M)	($101M)	($89M)	($51M)	($35M)	($40M)	($40M)	($45M)	($39M)	($28M)	($8M)	($33M)	($25M)	($18M)	($14M)	($13M)	($8M)	($13M)	($24M)	($20M)	($16M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$3M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($111M)	($101M)	($89M)	($51M)	($35M)	($40M)	($43M)	($45M)	($39M)	($29M)	($8M)	($33M)	($25M)	($18M)	($14M)	($14M)	($8M)	($13M)	($24M)	($20M)	($16M)
FCF Margin %	—	—	—	—	—	-4013800.0%	-16782.1%	—	—	—	-2094.5%	-61322222.2%	-1601550.4%	—	—	—	-1711.8%	-4205.5%	-4770.5%	-3954.1%	—
Dividends Paid	—	—	—	—	—	—	$2M	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVRA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($30M)	($33M)	($25M)	($23M)	($26M)	($27M)	($23M)	($23M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($30M)	($33M)	($25M)	($23M)	($26M)	($27M)	($23M)	($23M)
FCF Margin %	—	—	—	—	—	—	-8562.5%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVRA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$192M	$253M	$213M	$178M	$140M	$177M	$98M	$136M	$152M	$160M	$29M	$54M	$70M	$55M	$47M	$62M	$28M	$9M	$11M	$35M	$53M
Cash & Cash Equivalents	$42M	$33M	$15M	$27M	$52M	$34M	$23M	$50M	$24M	$22M	$13M	$23M	$36M	$26M	$23M	$44M	$28M	$9M	$10M	$15M	$26M
Total Liabilities	$48M	$50M	$41M	$37M	$32M	$32M	$33M	$35M	$152M	$40M	$65M	$30M	$12M	$7M	$5M	$5M	$2M	$2M	$5M	$4M	$33M
Total Debt (Short + Long-Term)	$30M	$30M	$27M	$26M	$26M	$26M	$25M	$26M	$25M	$15M	$3M	$15M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$144M	$203M	$171M	$140M	$108M	$144M	$64M	$102M	$108M	$119M	($36M)	$24M	$59M	$48M	$42M	$57M	$27M	$7M	$6M	$31M	$20M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SVRA viewer.

Other Companies in BIOTECHNOLOGY

ANRO · Alto Neuroscience, Inc. — $1 billion
ODTX · Odyssey Therapeutics, Inc. Common Stock — $1 billion
SPTX · Seaport Therapeutics, Inc. Common Stock — $1 billion
MNKD · MannKind Corp — $1 billion
OBX · Obsidian Therapeutics, Inc. Common Stock — $1 billion
JBIO · Jade Biosciences, Inc. — $1 billion
MLTX · MoonLake Immunotherapeutics — $1 billion
KURA · Kura Oncology Inc — $1 billion

← SVPGLOB All “S” companies SVRE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.